Clinical Trial Update: Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating VX-950 (telaprevir) in combination with Pegasys and Copegus for Hepatitis C has completed. The update notes the study status but d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)
• VX-950 (Telaprevir)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED